An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study.

Trial Profile

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2009

At a glance

  • Drugs Enoxaparin sodium; Rivaroxaban
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 23 Jun 2009 Actual end date (Nov 2004) added as reported by ClinicalTrials.gov.
    • 23 Jun 2009 Bayer HealthCare Pharmaceuticals added as trial affiliate and lead trial centre as reported by ClinicalTrials.gov.
    • 02 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top